Story perspectives

Acuitas Unveils Potent Lipid Nanoparticles for Cancer Vaccines

11/18/2025

42 7

Summary

Story summary

Acuitas Therapeutics presented Next-Generation lipid nanoparticles at the 13th mRNA Health Conference in Berlin, aiming to boost potency and safety.
The company reported improved mRNA delivery for cancer vaccines, achieving stronger immune responses at lower doses.
They identified six novel lipids that outperform their existing ALC-315 in immunogenicity.
In LNP tolerability studies in larger monkeys, premedications and body weight significantly affected safety.

1 of 1

Story summary

Acuitas Therapeutics presented Next-Generation lipid nanoparticles at the 13th mRNA Health Conference in Berlin, aiming to boost potency and safety.
The company reported improved mRNA delivery for cancer vaccines, achieving stronger immune responses at lower doses.
They identified six novel lipids that outperform their existing ALC-315 in immunogenicity.
In LNP tolerability studies in larger monkeys, premedications and body weight significantly affected safety.